|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
7/10/2007 12:47:35 PM
VENLO, The Netherlands, July 9, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (NasdaqGS:QGEN - News); (Frankfurt:QIA.F - News), the world's leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics, today announced that its subsidiary QIAGEN North American Holdings, Inc. has completed its acquisition of eGene, Inc. in a transaction at $0.65 in cash and 0.0416 common shares of QIAGEN stock per share of eGene common stock. The transaction has been publicly announced on April 12, 2007. The aggregate purchase consideration amounts to approximately $34.0 million and consists of $15.5 million in cash and 1.0 million common shares of QIAGEN stock valued at $17.0 million (based on the average closing prices of QIAGEN common shares on the NASDAQ Global Select Market for the 20 trading days ending on April 12, 2007), as well as the assumption of certain liabilities in the amount of approximately $1.5 million.
|
|
|
|
|
|
|
|
|
|
|